In the case of teplizumab, the treatment had been given to individuals newly diagnosed with (stage 3) type 1 diabetes in five previous trials with the aim of preserving endogenous insulin production and providing data on safety [24]. The gene discussed is INS; the disease is type 1 diabetes mellitus.